Last reviewed · How we verify
Phenylephrine Ophthalmic
At a glance
| Generic name | Phenylephrine Ophthalmic |
|---|---|
| Sponsor | University of Miami |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of 4 Methods of Eye Drops for Pupil Dilation in Diabetic Patients (NA)
- Clinical Determinants and Adverse Reactions to Tropicamide/Phenylephrine in Hospitalized Patients.
- Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation (PHASE4)
- Pharmacodynamics of a Fixed Dose Combination of 0.34% Tropicamide and 2.5% Phenylephrine Hydrochloride, Eye Drop, Solution (PHASE1, PHASE2)
- Retinal Vascular Changes in Patients After Coronavirus Disease 2019 (COVID-19)
- LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis. (PHASE3)
- Contribution of the Kinematic Theory in the Early Differential Diagnosis of the Parkinson's Disease
- Evaluation of Pupil Dilation Speed With the MAP Dispenser (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |